Dyne Therapeutics (DYN) AI Stock Analysis

• Market Cap: $1.30B
• Dividend Yield: N/A
• Average Volume (3M): 1.64M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.07
• Revenue Growth: N/A
• EPS Growth: 14.93%
• Country: US
• Employees: 141
• Sector: Healthcare
• Sector Strength: 78
• Industry: Biotechnology
• EPS (TTM): -3.35
• Shares Outstanding: 113,121,360
• 10 Day Avg. Volume: 1,791,067
• 30 Day Avg. Volume: 1,644,298
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -3.90
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $50.90
• Price Target Upside: 342.61% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 10

Dyne Therapeutics' overall stock score reflects its position as a high-risk, high-reward biotech investment. Strong cash reserves and low leverage support its R&D efforts despite current financial losses. Technical indicators and valuation metrics highlight current challenges, yet promising clinical trial progress could transform its future value.

Positive Factors

Clinical Data

DYNE-101 for DM1 represents DYN major valuation driver and investor focus with acceptable safety and promising efficacy.

Regulatory Pathway

Fast track designation for DYNE-101 highlights unmet need and enables more frequent FDA interactions with potential for priority review and accelerated approval.

Negative Factors

Data Variability

The low number of patients might have added to the noise seen in the CASI 22 data at 6 months mostly due to missing baseline data and intra patient variability.

Investor Sentiment

Investor sentiments reflect uncertainty over the 6.8 mg/kg being chosen as the registrational dose.

Dyne Therapeutics Business Overview & Revenue Model

Company Description

Dyne Therapeutics (DYN) is a biotechnology company focused on developing targeted therapies for patients with genetically driven diseases. The company specializes in advancing innovative treatments for rare muscle disorders, leveraging its proprietary FORCE platform to deliver nucleic acid therapeutics precisely to muscle tissue. Dyne's pipeline includes programs aimed at treating conditions such as Duchenne muscular dystrophy, myotonic dystrophy type 1, and facioscapulohumeral muscular dystrophy.

How the Company Makes Money

Dyne Therapeutics generates revenue primarily through strategic collaborations, partnerships, and licensing agreements with other biotechnology and pharmaceutical companies. These partnerships often involve upfront payments, milestone payments for achieving specific clinical or regulatory goals, and royalties on sales of any successfully commercialized products. Additionally, Dyne may receive funding through research grants and government contracts aimed at advancing its therapeutic programs. As the company progresses towards commercialization, potential revenue streams could also include direct sales of approved therapies or sublicensing opportunities with other entities.

Dyne Therapeutics Financial Statement Overview

Summary

Dyne Therapeutics shows typical characteristics of a pre-revenue biotech company with a strong balance sheet, high R&D expenses, and substantial cash reserves. While the income statement reveals increasing losses, cash flow is negative but mitigated by successful equity financing.

Income Statement

Dyne Therapeutics has consistently reported zero revenue over the years, reflecting its early-stage position in the biotechnology sector focused on R&D. The company incurs substantial net losses, which have been increasing over time, indicating high operational expenses without offsetting revenue streams. This results in negative profit margins across all metrics, which is typical for a biotech firm in the pre-commercial phase.

Balance Sheet

The balance sheet is relatively strong with a significant amount of cash and short-term investments, which is crucial for sustaining R&D activities. The company maintains low debt levels relative to its equity, reflected in a healthy debt-to-equity ratio. A robust equity ratio indicates a strong capital structure, providing financial stability and reducing immediate liquidity risks.

Cash Flow

Cash flows are deeply negative, driven by heavy R&D investments, a common scenario for pre-revenue biotech companies. However, the substantial cash on hand and positive financing cash flow from equity funding highlight the company's ability to raise capital, enabling it to continue its development projects despite negative free cash flow growth.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00
	Gross Profit
0.00	-2.46M	-3.35M	-1.09M	-700.00K
	EBIT
-343.89M	-242.16M	-170.96M	-150.03M	-58.65M
	EBITDA
-343.89M	-233.48M	-164.75M	-148.20M	-58.34M
	Net Income Common Stockholders
-317.42M	-235.94M	-165.24M	-149.28M	-58.74M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
642.27M	123.10M	256.01M	376.57M	345.31M
	Total Assets
691.23M	165.08M	306.32M	425.66M	353.33M
	Total Debt
23.99M	27.41M	30.48M	32.64M	0.00
	Net Debt
-411.46M	-94.21M	-141.66M	-168.19M	-300.85M
	Total Liabilities
61.40M	73.79M	53.96M	57.47M	10.97M
	Stockholders Equity
629.84M	91.29M	252.36M	368.20M	342.37M
Cash Flow		Free Cash Flow
-294.75M	-188.89M	-156.71M	-123.18M	-47.67M
	Operating Cash Flow
-292.37M	-188.16M	-153.65M	-119.56M	-46.51M
	Investing Cash Flow
-204.08M	83.31M	87.20M	-137.89M	-45.66M
	Financing Cash Flow
809.89M	54.32M	37.39M	157.82M	380.69M

Dyne Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 11.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DYN, the sentiment is Negative. The current price of 11.5 is below the 20-day moving average (MA) of 13.16, below the 50-day MA of 15.74, and below the 200-day MA of 29.89, indicating a bearish trend. The MACD of -1.10 indicates Negative momentum. The RSI at 35.91 is Neutral, neither overbought nor oversold. The STOCH value of 21.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DYN.

Dyne Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BMRN	77 Outperform	$13.74B	32.75	8.05%	―	17.35%	151.40%
SRPT	69 Neutral	$9.67B	41.83	19.71%	―	52.97%	―
VRTX	64 Neutral	$128.40B	―	-3.15%	―	11.64%	-114.72%
PTCT	56 Neutral	$4.14B	―	33.08%	―	-13.97%	43.51%
IONS	49 Neutral	$5.12B	―	-93.03%	―	-10.48%	-18.79%
Sector *	49 Neutral	$6.90B	-0.08	-53.01%	2.43%	24.84%	-3.06%
DYN	41 Neutral	$1.30B	―	-88.03%	―	―	14.93%

Dyne Therapeutics Corporate Events

Dyne Therapeutics Advances Clinical Trials for DM1 and DMD

Dyne Therapeutics has reported promising clinical data from its Phase 1/2 ACHIEVE trial of DYNE-101, targeting myotonic dystrophy type 1 (DM1), showing significant improvements in disease biomarkers and functional endpoints. The company plans a global Registrational Expansion Cohort to support a U.S. Accelerated Approval submission in 2026, highlighting the potential of DYNE-101 to transform treatment paradigms for DM1. Additionally, in the DELIVER trial for DYNE-251, targeting Duchenne muscular dystrophy, the company revealed favorable safety data and plans to pursue accelerated approval pathways, with submissions expected early in 2026.